Introduction {#Sec1}
============

At the end of 2019, an outbreak of a highly contagious viral pneumonia was reported in Wuhan, China, and the causative agent was confirmed to be a novel coronavirus, termed as COVID-19 by the World Health Organization \[[@CR1]\]. The disease spread to all provinces in China and many countries overseas, leaving more than 400,000 people infected as of March 25, 2020 \[[@CR2], [@CR3]\]. Jiangsu Province has the fifth largest population in China and has reported more than 600 infected cases \[[@CR4]\].

Computed tomography (CT) examination plays an important role in the evaluation of COVID-19. According to the 5th edition of diagnosis and treatment standards for novel coronavirus pneumonia published by the Chinese National Health Commission, CT examination is one of the three main diagnostic criteria. In Hubei Province, the clinical diagnosis of COVID-19 comprises only clinical and radiological proof, irrespective of the nucleic acid test result, thus highlighting the importance of CT imaging assessment \[[@CR5]\].

Some typical radiological findings including subpleural ground-glass opacities (GGO) and consolidation have been reported as well as the dynamic evolution of these lesions \[[@CR6]--[@CR10]\]. However, these measurements were mainly based on visual evaluation, which are subjective and inaccurate. In addition, imaging evolution according to disease severity has rarely been reported, which we believe is critical for understanding the nature of the disease and monitoring disease change in a stratified manner.

In this retrospective study, quantitative assessment of imaging characteristics and dynamic evolution was evaluated. Comparison was made among patients with variable disease severity.

Materials and methods {#Sec2}
=====================

This study was approved by the ethics committee of Zhongda Hospital (2020ZDSYLL013-P01 and 2020ZDSYLL019-P01), and informed consent was waived due to the emergent event of the pandemic.

Clinical information and imaging data for all COVID-19 patients diagnosed in Jiangsu before February 18, 2020, were obtained, retrospectively from electronic medical records, established by the Department of Health, Jiangsu Province.

Patients with no clinical records or with missing, incomplete, or poor-quality chest CT images were excluded. Figure [1](#Fig1){ref-type="fig"} shows the detailed flowchart of this study.Fig. 1Flowchart of the study

Based on the 5th edition of the guideline for the diagnosis and treatment of COVID-19, published by the National Health Commission of the People's Republic of China on February 8, 2020, patients were assigned into three groups, classified according to disease severity: asymptomatic/mild, moderate, or severe/critically ill. Patients were classified as (i) "asymptomatic" if they had no symptoms of disease, (ii) "mild" if they had mild clinical symptoms, but no imaging abnormality, and (iii) "moderate" if they had one or more symptoms (fever, cough, diarrhea, etc.), and imaging showed manifestations of pneumonia or (iv) "severe" if they had one of the following conditions: (a) respiratory distress presenting with respiratory rate ≥ 30 beats/min, (b) mean oxygen saturation in resting state ≤ 93%, (c) arterial blood oxygen partial pressure/oxygen concentration ≤ 300 mmHg. (v) Patients with either shock, respiratory failure requiring mechanical ventilation, or combined organ failure requiring admission to an intensive care unit (ICU) were classified as "critically ill."

In order to analyze the evolution of imaging and clinical characteristics, the day when the initial symptoms emerged was defined as day 1. When no initial symptoms were reported, the date of outpatient visit was used as day 1. The time points for each CT scan, change of severity grading relative to day 1, were recorded and were further assigned to days 1--3, days 4--6, days 7--9, days 10--12, days 13--15, and beyond day 15.

CT acquisition {#Sec3}
--------------

CT imaging was performed using multislicer CT scanners. Thin-section images were collected preferentially (for further details relating to the acquisition of CT images, please see Table [S1](#MOESM1){ref-type="media"}). All raw data with format of Digital Imaging and Communications in Medicine were then transferred to work stations for post-processing.

Imaging analysis {#Sec4}
----------------

Lung segmentation, lesion extraction, and labeling were performed using a dedicated artificial intelligence (AI) system with deep learning algorithm for pulmonary pneumonia (Deepwise & League of PhD Technology Co., Ltd.). The AI algorithm achieved a dice of 0.97 in the HOUSE dataset (easy) and 0.89 in the LOLA dataset (hard), which proved its robustness. The accuracy of the AI system in lesion extraction and labeling was also manually checked by an investigator (Y.W.) with more than 10 years of experience in chest imaging. Bilateral lungs were segmented into the right upper lobe, right middle lobe, right lower lobe, left upper lobe, and left lower lobe automatically, and extraction of pulmonary opacities was carried out at the same time. All extracted opacity pieces were annotated as GGO or consolidation by the AI system and were approved by an investigator (Y.W.). The masks of opacities and each lung's lobes were saved for further voxel-based measurements including volume, X-ray attenuation, and location. Detailed information regarding segmentation and lesion extraction are available in [supplemental methods](#MOESM1){ref-type="media"}.

Further assessment of segmented lobes and extracted opacities was performed as follows:Volume measurement: it included volume of bilateral lungs, GGO, consolidation, GGO + consolidation, and aerated lung.Density measurement: it included the X-ray attenuation of bilateral lungs, overall opacities, opacities in upper lobes including bilateral upper lobes and right middle lobe, and opacities in bilateral lower lobes.Location analysis: A standard lung was selected from a healthy 37-year-old male without lung abnormalities. Subsequent registration and projection of all included chest CT images to the standard lung was performed. Voxel-based frequencies of opacity were measured by drawing five volumes of interest (VOIs) in the standard lung, with each of the VOI larger than 15 mL. Four VOIs were placed in the subpleural areas (within 15 mm from the pleura), which were the right posteroinferior subpleural area, right posterosuperior subpleural area, right anterior subpleural area, and right medial subpleural area, and the last one was placed in the right central area 20 mm away from the pleura (Fig. [S1](#MOESM1){ref-type="media"}). The number of lobes with pulmonary opacities was also recorded and scored from 0 to 5, with 5 indicating all 5 lobes were involved.Dynamic evolution: Dynamic changes of volume, density, and frequency of opacities by location from symptom onset (day 1) to beyond day 15 were investigated.

Clinical and laboratory characteristics {#Sec5}
---------------------------------------

Demographic information, exposure type, initial symptoms (fever, cough, sputum, shortness of breath, dyspnea, anorexia, or diarrhea), possible exposure time, time of initial symptoms, date of admission to hospital, comorbidity, and clinical laboratory findings including arterial oxygen saturation (SaO~2~), blood cell counts (blood leukocyte count, lymphocyte count, and platelet count), and biomarkers of inflammation (C-reactive protein level, procalcitonin level, lactate dehydrogenase), hepatic and renal function (aspartate aminotransferase level, alanine aminotransferase level, creatinine level), and coagulation (D-dimer level) were collected.

Statistical analysis {#Sec6}
--------------------

All consecutive data were listed as means ± standard deviations (SDs) or medians with interquartile ranges (IQRs) for Gaussian and skewed distributed data. Skewed distributed data were tried to convert to Gaussian distribution by logarithmic transformation for variance analysis. The Chi-square test, Kruskal-Wallis test, or Mann-Whitney test was used to examine statistical differences for ratio and skewed distributed data. All statistical analyses were performed using the R statistical software version 3.0.3.

Results {#Sec7}
=======

A total of 626 patients diagnosed with COVID-19 from 24 designated hospitals in Jiangsu Province were initially recruited to this study. One hundred and forty-two patients were excluded from the study because of either no clinical records or missing or incomplete chest CT images, or images with poor quality (Fig. [1](#Fig1){ref-type="fig"}). The remaining 484 patients from 21 hospitals (3 were excluded) were assigned to three severity groups (asymptomatic/mild, *n* = 63; moderate, *n* = 378; severe/critically ill, *n* = 43). Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. There was marked disparity in median age between the three groups, manifesting as an increased age with increased severity (*p* \< 0.001). Fever (up to 83.7%) and cough/sputum (up to 69.8%) were the most common symptoms in symptomatic patients. Analyses of laboratory test results for SaO~2~, blood leukocyte count, lymphocyte count, and platelet count showed downward trends from asymptomatic/mild to severe/critically ill. Conversely, C-reactive protein, lactate dehydrogenase, aspartate aminotransferase, and D-dimer concentrations above the normal range (≥ 10 mg/L, ≥ 250 U/L, \> 40 U/L and ≥ 0.5 mg/L, respectively) tended to be more common in patients with severe disease. Patients with severe disease tended to have more adverse events including admission to ICU, invasive mechanical ventilation, continuous renal replacement therapy, and extracorporeal membrane oxygenation (34.9%, *p* \< 0.001).Table 1Baseline characteristics of study patientsCharacteristicsDisease severityAsymptomatic/mild (*n* = 63, 13.0%)Moderate (*n* = 378, 78.1%)Sever/critically ill (*n* = 43, 8.9%)*p* valueAge (years)33 (22, 51)46 (34, 56)59 (52, 71)\< 0.001Gender, male31/63 (49.2%)202/378 (53.4%)27/43 (62.8%)0.377Incubation period (days)8 (5, 11)6 (3, 10)5 (3, 8)0.125Initial symptoms  Fever14/30 (46.7%)^c^278/378 (73.5%)36/43 (83.7%)\< 0.001  Cough/sputum19/30 (63.3%)^c^224/378 (59.3%)30/43 (69.8%)\< 0.001  Shortness of breath/dyspnea0/30 (0%)^c^10/378 (2.7%)5/43 (11.6%)0.007Comorbidity^a^8/63 (12.7%)76/378 (20.1%)16/43 (37.2%)0.008Exposure type  Wuhan exposure18/63 (28.6%)148/378 (39.2%)16/43 (37.2%)0.275  COVID-19 patients exposure34/63 (54.0%)139/378 (36.8%)12/43 (27.9%)0.012  Contact history^b^8/63 (12.7%)40/378 (10.6%)8/43 (18.6%)0.284  No exposure3/63 (4.8%)51/378 (13.5%)7/43 (16.3%)0.116Type of disease  Single onset10/63 (15.9%)199/378 (52.6%)23/43 (53.5%)\< 0.001  Clustering onset53/63 (84.1%)179/378 (47.4%)20/43 (46.5%)\< 0.001Laboratory tests  SaO~2~ (%)98.2 (98.0, 98.4)97.9 (96.4, 99.0)95.3 (93.2, 97.3)\< 0.001  Blood leukocyte count (× 10\^9/L)5.3 (4.5, 6.6)4.8 (3.8, 6.0)4.2 (3.5, 5.9)0.033    \< 4 × 10\^9/L9/57 (15.8%)93/309 (30.1%)14/37 (37.8%)0.040    \> 10 × 10\^9/L1/57 (1.8%)5/309 (1.6%)3/37 (8.1%)0.077  Lymphocyte count (× 10\^9/L)1.8 (1.3, 2.5)1.3 (1.0, 1.7)0.6 (0.5, 0.9)\< 0.001    \< 1.5 × 10\^9/L18/54 (33.3%)195/318 (61.3%)36/37 (97.3%)\< 0.001  Platelet count (× 10\^9/L)216 (164, 263)182 (152, 212)154 (120, 191)\< 0.001    \< 150 × 10\^9/L9/58 (15.5%)71/322 (22.0%)15/37 (40.5%)0.014  C-reactive protein (≥ 10 mg/L)4/50 (8.0%)143/300 (47.7%)19/31 (61.3%)\< 0.001  Procalcitonin (≥ 0.5 ng/mL)5/50 (10.0%)55/295 (18.6%)6/27 (22.2%)0.274  Lactate dehydrogenase (≥ 250 U/L)6/37 (16.2%)103/232 (44.4%)17/26 (65.4%)\< 0.001  Aspartate aminotransferase (\> 40 U/L)4/48 (8.3%)71/270 (26.3%)13/30 (43.3%)0.002  Alanine aminotransferase (\> 40 U/L)6/46 (13%)70/273 (25.6%)8/30 (26.7%)0.170  D-dimer (≥ 0.5 mg/L)11/54 (20.4%)75/311 (24.1%)17/36 (47.2%)0.007  Creatine (μmol/L)63 (47, 79)63 (50, 78)62 (51, 82)0.975ICU /IMV/CRRT/ECMO1/63 (1.6%)13/378 (3.4%)15/43 (34.9%)\< 0.001Categorical variables are expressed as number (percentage) while continuous variables are described as median and interquartile range*ICU* intensive care unit, *IMV* invasive mechanical ventilation, *CRRT* continuous renal replacement therapy, *ECMO* extracorporeal membrane oxygenation^a^Comorbidity include hypertension, coronary heart disease, cardiac dysfunction III--IV, poor physical fitness (unable to climb stairs, do daily housework, etc.), gastrointestinal hemorrhage caused by cirrhosis, hepatic encephalopathy and portal hypertension, diabetes, chronic kidney dysfunction, dialysis, malignant tumor, hematological malignancies, connective tissue disease, and stroke^b^Contact history refers to those patients who had contact with people from Wuhan before the onset of disease^c^A total of 33 patients were asymptomatic in the asymptomatic/mild group and were excluded when calculating the symptom percentage

Imaging characteristics by severity {#Sec8}
-----------------------------------

A total of 954 CT scans were performed in the 484 patients (asymptomatic/mild 122 \[12.8%\], moderate 747 \[78.3%\], severe/critically ill 85 \[8.9%\]). Numbers of CT scans by disease severity and time points are illustrated in Fig. [S2](#MOESM1){ref-type="media"}. The imaging characteristics are shown in Table [2](#Tab2){ref-type="table"}. Among the asymptomatic/mild group, 14.8% of CT scans showed no abnormal findings, and this was significantly greater than for the other two groups (*p* \< 0.001). When pooling CT scans at different time points together, volume, density, and location demonstrated significant differences between the three groups. The severe/critically ill group showed the lowest total lung volume and aerated lung and greatest volume of pulmonary opacities with 3548.7 mL, 2557.0 mL, and 491.4 mL, respectively. For different components and locations of opacities, volume of consolidation was more than GGO and volume of opacities in the lower lungs were more than that in the upper lungs. Declines were found in attenuation as disease severity decreased.Table 2Computed tomography (CT) results in patients with COVID-19, according to disease severityCharacteristicsDisease severityAsymptomatic/mild (*n* = 63, 13.0%)Moderate (*n* = 378, 78.1%)Severe/critically ill (*n* = 43, 8.9%)*p* valueNumber of chest CT examinations122/954 (12.8%)747/954 (78.3%)85/954 (8.9%)-Number of CT examinations without pulmonary opacity18/122 (14.8%)15/747 (2.0%)0/85 (0%)\< 0.001Number of CT examinations with slice thickness ≤ 3 mm114/122 (93.4%)654/747 (87.6%)72/85 (84.7%)0.108Volume (mL)  Whole lung4637.4 (3687.7, 5724.5)4429.7 (3575.9, 5338.5)3548.7 (2538.3, 4393.6)\< 0.001  Aerated lung4636.0 (3585.6, 5647.4)4216.6 (3307.1, 5094.7)2557.0 (1921.0, 3921.7)\< 0.001  Pulmonary opacities1.7 (0.1, 44.9)129.8 (34.0, 302.5)491.4 (199.0, 1041.0)\< 0.001  Ground-glass opacities0.1 (0, 5.7)9.1 (1.2, 32.5)14.8 (0.9, 66.4)\< 0.001  Consolidation0.4 (0, 20.3)97.5 (16.8, 238.8)437.3 (134.2, 977.8)\< 0.001  Opacities in the upper lobes0 (0, 1.8)22 (0.7, 98.7)227.7 (46.6, 496.2)\< 0.001  Opacities in the lower lobes0 (0, 28.7)76.2 (13.8, 190.1)288.3 (102.4, 554.6)\< 0.001Density (X-ray attenuation, Hu)  Whole lung− 847 (− 864, − 821)− 826 (− 856, − 786)− 750 (− 802, − 684)\< 0.001  Pulmonary opacities− 602.5 (− 713, − 484)− 634 (− 711, − 540)− 576 (− 666, − 523)0.003  Opacities in the upper lobes− 656 (− 736, − 566)− 676 (− 744, − 577)− 634 (− 696, − 560)0.009  Opacities in the lower lobes− 586 (− 689, − 479)− 624 (− 708, − 518)− 534 (− 645, − 443)\< 0.001Frequencies of opacity by location (%)  Right posteroinferior subpleural area4.7 (2.4, 7.1)20.5 (18.6, 22.6)45.3 (43.0, 48.8)\< 0.001  Right posterosuperior subpleural area1.6 (0.8, 1.6)10.8 (8.5, 12.6)32.6 (29.1, 34.9)\< 0.001  Right anterior subpleural area1.6 (1.6, 3.1)5.3 (4.4, 6.6)24.4 (20.9, 26.7)\< 0.001  Right medial subpleural area1.6 (1.6, 1.6)4.1 (3.5, 5.2)22.1 (19.8, 26.7)\< 0.001  Right central area1.6 (0.8, 1.6)4.9 (4.5, 5.5)26.7 (23.3, 27.9)\< 0.001Lung lobes involved3 (1, 4)5 (3, 5)5 (5, 5)\< 0.001Variables are described as number (percentage) or median and interquartile range. Upper lobes include left upper lobe, right upper lobe, and right middle lobe; Lower lobes include left lower lobe and right lower lobe

Heterogeneous distribution of the pulmonary opacities was observed in all groups. The most common location for opacities was the subpleural area of posteroinferior lung (Fig. [S3](#MOESM1){ref-type="media"}), most prominently in the severe/critically ill group with frequency of 45.3%, followed by the subpleural area of posterosuperior lung (32.6%); the other areas (anterior and medial subpleural areas, central area) were comparable with frequencies of 22.1 to 26.7%. The frequencies dropped with decreased disease severity, in all locations of the lung (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Three-dimensional heat maps show the frequency of location of pulmonary opacities in COVID-19 from the onset of symptoms (day 1) to beyond day 15. Asymptomatic/mild patients have trace opacities, resolving partially after 15 days (top row). Moderately ill patients have more opacities and peaked on days 13--15, predominantly located in the posteroinferior subpleural area (middle row). Severe/critically ill patients have the most prominent opacities and continue to progress beyond day 15 (bottom row). Axial frequency map shows a typical pattern of posterior subpleural distribution of the opacities with decreased frequency in the anterior and medial subpleural areas

In patients in the severe/critically ill group, significantly more lung lobes were involved compared with the other two groups, with the median number of lobes of 5 (5 to 5), 5 (3 to 5), and 3 (1 to 4), respectively (*p* \< 0.001).

Dynamic evolution of imaging characteristics {#Sec9}
--------------------------------------------

The three groups showed different progressive and regressive imaging patterns (see [supplemental video](#MOESM2){ref-type="media"}).

The opacity volume was the greatest in the severe/critically ill group during the whole study period (Fig. [3a](#Fig3){ref-type="fig"}). Time series showed that opacity volumes (mainly for consolidation) continued to increase in the severe/critically ill group, reaching 30.3% of the whole lung beyond day 15. However, for the moderate group, opacity volume maintained a steady state after days 13--15, accounting 7.7% of the whole lung. In the asymptomatic/mild group, the highest opacity volume was on days 1--3 (mean 1.9%, 95% confidence intervals \[CI\] 3.2%), which dropped gradually to the lowest level beyond day 15 (mean 0.9%, 95% CI 0.3%) (Fig. [3b](#Fig3){ref-type="fig"}). When classifying the opacities into GGO and consolidation, a remarkable decrease trend of GGO was observed compared with the increase trend of consolidation in the severe/critically ill group.Fig. 3**a**--**d** CT measurements changing by day. **a** In the severe/critically ill group, volume of aerated lung decreased while pulmonary opacities increased by day. **b** Volume of consolidation kept growing beyond 15 days in the severe/critically ill group, while peaked on days 13--15 in the moderate group. **c** The density of opacities dropped after day 12 in the moderate group; opacities in lower lobes had higher attenuation than those in upper lobes. **d** Posteroinferior subpleural area was the most commonly involved location in the lung, and the variation trend was similar to volume change in **b**

In the moderate group, the attenuation showed a trend of increase in the initial 9 days after symptom onset and decrease after day 12. Overall median attenuation in the severe/critically ill group was significantly higher than in the moderate group (− 576 HU vs − 634 HU, *p* = 0.002). Opacities in the lower lobes had higher attenuation than that in the upper lobes (− 534 HU vs − 634 HU for the severe/critically ill group, − 624 HU vs − 676 HU for the moderate group, *p* \< 0.001). An increase trend of attenuation was perceived beyond day 15 in the severe/critically ill group, compared with continuous decline in the moderate group (Figs. [3c](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}).Fig. 4A 64-year-old male diagnosed with moderate COVID-19. Non-contrast chest CT were performed on days 5, 8, 10, and 15 after the onset of initial symptoms (**a**--**d**). The pulmonary opacities kept similar volume while the density decreased heterogeneously on day 15 compared with day 10

Change of opacity frequency by day synchronized with the volume, most evidently in the posteroinferior subpleural area, reaching 61.6% in the severe/critically ill group, verses 25.1% and 5.5% in the moderate and the asymptomatic/mild groups, respectively (Figs. [3d](#Fig3){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).Fig. 5A 56-year-old female diagnosed with severe COVID-19. Non-contrast chest CT were performed on days 5, 11, 14, and 17 after the onset of initial symptoms (**a**--**d**). The bilateral subpleural opacities progressed to consolidation on day 17

Discussion {#Sec10}
==========

In this province-based multicenter study, we have described CT imaging patterns and dynamic evolution in patients with COVID-19, according to disease severity. Jiangsu, an eastern Chinese province, with an area of 40,000 square miles and a population of about 80 million (ranked fifth in China provinces), is a representative district, and our findings may be of relevance to many other countries. The low death toll (no deaths in this study) and high proportion of patients with moderate disease severity due to COVID-19 observed in our study are similar to reports from many other countries \[[@CR2]\] and may indicate the common nature of COVID-19.

The demographics and clinical/laboratory findings in our study are also comparable with previously reported data \[[@CR3], [@CR8], [@CR11]\]. Severe cases tended to be older; had a shorter incubation period; had more comorbidities, abnormal blood cell counts, abnormal inflammatory biomarkers, and liver dysfunction; and experienced more serious adverse events. The early CT findings (3 days after onset) in this study were characterized as predominately subpleural GGO and posterior basal predominance for patients with different disease severity, consistent with previous studies \[[@CR6], [@CR12]\].

There was a tendency of subpleural distribution for pulmonary opacities, consistent with the underlying pathogenic pattern that distal bronchioles as well as alveolar epithelial cells impaired in viral pneumonia \[[@CR13], [@CR14]\]. The posterior basal predominance shown in the heat map may due to the predilection of atelectasis posteriorly, corresponding to heterogeneous pulmonary opacity distribution in patients with acute respiratory distress syndrome \[[@CR15]\]. Among all subpleural areas, the posteroinferior area of the lung showed leading frequency of opacity distribution as indicated in Fig. [3d](#Fig3){ref-type="fig"}, which may due to the anatomical characteristics of the bronchus: more vertical for lower lobes compared with the other lobes. This makes the lower lobes more susceptible to pathogen attack \[[@CR8]\]. Our study further demonstrated a discrepancy in subpleural distribution which has not been elaborated in previous studies: the medial and anterior subpleural areas were less frequently involved compared with the posterior subpleural areas.

Part of the pulmonary opacities presented as GGO in this study, especially in the early stages of disease. This finding is consistent with several studies \[[@CR8], [@CR10], [@CR16]--[@CR18]\]. Although our understanding of the pathological mechanisms and effects of this specific novel coronavirus is limited, there is some evidence to explain the underlying causes of these radiological manifestations. In a study of two patients with lung adenocarcinoma surgery superimposed with COVID-19, damage of alveoli, together with proteinaceous and fibrous exudation, accounted for the early appearance of GGO on chest CT \[[@CR19]\]. In studies of severe acute respiratory syndrome (SARS), focal lung injury was related to early radiologic findings \[[@CR20]\]. As SARS and COVID-19 are both caused by coronavirus, it is possible that some of their pathological process overlap \[[@CR21]\]. As the disease progresses, more inflammatory cells infiltrate the alveoli and interstitial space, followed by diffuse alveolar damage and hyaline membrane formation \[[@CR22]\], which result in an appearance of consolidation on CT examination.

As for the dynamic evolution, a study of 63 COVID-19 patients from Wuhan showed an increased range of GGO and consolidation in 3--14 days after onset of symptoms \[[@CR17]\]. Pan et al identified a peak stage of 9--13 days for lung involvement after symptom onset in 21 patients \[[@CR10]\], compared with 6--11 days from another study of 90 patients \[[@CR9]\]. In our study, we used an AI algorithm to automatically and quantitatively measure the percentage of opacity volume in 484 patients, which is different from scoring system based on visual evaluation in previous studies \[[@CR9], [@CR10], [@CR17]\]. We concluded a peak stage of 13--15 days for opacity volume after symptom onset in moderately ill patients---the large majority in this study. Notably, for severe/critically ill patients, this peak stage extended to beyond 15 days, while for mild/asymptomatic patients, the peak stage was just at the first 3 days after symptom onset. In severe/critically ill patients, different evolution patterns for GGO and consolidation were observed. There was a trend that GGO reduced continuously along with consolidation aggregation, suggesting a transformation of GGO to consolidation, during the course of disease. Varied patterns of imaging evolution are particularly useful in dynamically evaluating disease severity.

AI has been developed fast in recent years and has already been used to distinguish pneumonia in COVID-19 from community-acquired pneumonia \[[@CR23]\]. The preliminary results are promising, but it should be noted the pre-test probability of COVID-19 varied with cities as well as countries, and the positive predictive value of CT, even combined with AI, may low in areas with low pre-test probability \[[@CR24]\]. It should be avoided to overstate the role of AI in the diagnosis of COVID-19. In this study, however, we did not use AI to diagnose COVID-19, but for pulmonary lobe segmentation, lesion extraction, and GGO/consolidation labeling, these techniques are relatively mature. And the accuracy was verified in the study.

Our retrospective study has several limitations. Firstly, prospective studies of CT examination and patterns of evolution should be undertaken and validated in more institutions. Secondly, the relatively small sample size of mild/asymptomatic cases resulted in relatively large variation in certain measurements. Consequently, although trends for some changes were observed, they did not reach statistical significance. Therefore, further studies that include more patients with asymptomatic/mild disease cases are required to strengthen the statistical power. Thirdly, opacity changes on CT were still progressing in the severe/critically ill patient group at the end of the study period (beyond day 15). Therefore, further studies are required to prolong the follow-up period to determine the potential break point for these patients. Finally, since CT findings were significantly different between the severity groups, we hypothesize that a combined CT score could be developed to classify disease severity, and predict disease outcome at an early stage. We plan to undertake this work in the near future.

Conclusion {#Sec11}
==========

In this multicenter study of patients with COVID-19, we have shown that pulmonary opacities vary in volume, density, and location, as well as the dynamic evolution, according to disease severity. Our findings provide insight into the nature of the disease and are potentially valuable in the evaluation and monitoring of the disease.
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